This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Smith & Nephew's Rotation Medical Deal Aids Tissue Regen Arm
by Zacks Equity Research
Smith & Nephew's (SNN) completion of Rotation Medical acquisition appears highly strategic as this will consolidate the company's position in disruptive technologies and advance its overall growth.
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic and Smith & Nephew
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic and Smith & Nephew
MedTech Industry Outlook - October 2017
by Zacks Equity Research
The Trump administration has not come up with any concrete plan to replace the MedTech tax as of yet.
Graham-Cassidy Fail Shines Spotlight on 3 Top Dividend Stocks
by Zacks Equity Research
Zeroing in on dividend stocks with a solid Zacks Rank is a great way to increase the chances of beating volatile market conditions while ensuring a steady stream of cash flow. Here are three top picks in the MedTech space.
The Zacks Analyst Blog Highlights: Cardinal Health, Penumbra, STAAR Surgical, Masimo and Smith & Nephew
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cardinal Health, Penumbra, STAAR Surgical, Masimo and Smith & Nephew
Top MedTech Stocks Safe from Graham-Cassidy Repeal Bill
by Zacks Equity Research
The investment climate for medical device majors has become increasingly volatile due to political potshots in Capitol Hill, for and against Obamacare.
Republicans Take Last Shot at Obamacare: 5 MedTech Stocks to Buy
by Zacks Equity Research
The fate of Obamacare will be decided on Sep. 30. No matter what the future holds, the day will provide investors a clear picture of where the MedTech industry is headed.
MedTech Hangs in the Balance as Obamacare Skinny Repeal Fails
by Zacks Equity Research
Any retention or repeal of Obamacare will actually create a vicious circle within the MedTech sector.
5 British Stocks to Profit From a Weak Pound Sterling
by Swarup Gupta
Companies exporting products and services stand to benefit from a weaker pound.
3 MedTech Stocks Set to Rally in the Second Half
by Zacks Equity Research
The wide gamut of Medical Device presents interesting choice for investors to profit from rally in the second half of 2017.
Anika (ANIK) Grows in Orthopedic Medicines on Positive Data
by Zacks Equity Research
Anika Therapeutics' (ANIK) data shows HYALOFAST as an effective treatment option for cartilage lesions, suitable to all age groups.
Medical Product Stocks Q1 Earnings Slated on May 5: VWR, SNN
by Zacks Equity Research
Let's take a look at the major Medical products stocks slated to release their first-quarter 2017 reports on May 5.
MedTech Industry Stock Outlook - March 2015
by Zacks Equity Research
Emerging market expansion, positive demographic trends and new product innovation have been the vital forces behind the continued uptrend of the sector's performance.
MedTech Industry Stock Outlook - March 2015
by Zacks Equity Research
Emerging market expansion, positive demographic trends and new product innovation have been the vital forces behind the continued uptrend of the sector's performance.
MedTech M&As Continue Regardless of Tax Scenarios
by Zacks Equity Research
MedTech stalwarts are not expected to shy away from hostile acquisition bids this year.